Radiopharmaceutical biotech firm Isotope Technologies Munich (ITM) has appointed Celine Wilke, MD, as its chief medical officer.
In a statement, the company said that Wilke will lead the clinical development and medical teams in bringing ITM-11, ITM’s targeted radionuclide therapy agent for neuroendocrine tumors, toward potential market approval, as well as further accelerating the development of other radiopharmaceuticals in the company’s precision oncology pipeline.
ITM-11 is currently under investigation in a phase III clinical trial (COMPETE).
Wilke specializes in clinical pharmacology and oncology and has nearly 20 years of industry experience. She previously oversaw clinical trials for radiopharmaceutical therapies and imaging compounds as Senior Global Program Clinical Head for prostate cancer at Novartis. Prior to her roles working for Novartis, Wilke was Head of Clinical Drug Development and Regulatory Affairs at MediGene.
